Neuraxpharm launches first probiotic product PS128™

New collaboration between Neuraxpharm and Bened Biomedical expands portfolio of Consumer Healthcare products

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces it will soon launch its first probiotic [1] in the European market following an exclusive licensing agreement with the probiotics company Bened Biomedical Co., Ltd.

Bened Biomedical, an award winning 2015 spin-out from Taiwan-based National Yang-Ming University, develops functional probiotic strains that can alter human microbiome. The agreement secures Neuraxpharm exclusive rights to market its first probiotic, PS128™, in the European market.

This is Neuraxpharm’s first launch of a probiotic product expanding the Company’s portfolio of marketed Consumer Healthcare products. This is in line with its ambition of covering CNS therapeutics from prevention over standard therapeutics to value-added medicines. As the European Consumer Healthcare market continues to grow, this agreement opens new opportunities to promote the benefits of a broader range of probiotics to healthcare professionals and consumers.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...